DanielCostaMD

PubMed

• A Real-World Study of Patient Characteristics and Clinical Outcomes inMutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into ...
  Emmeline Academia, Susumu S Kobayashi, Hollis Viray, Andrew J Piper-Vallillo, Page Widick, Meghan Shea, Deepa Rangachari, Paul A VanderLaan, Daniel B Costa> ;Cancers. 2024 Mar 7
• The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors.
  Kobayashi, I., Shaffer, W., Kobayashi, S., Viray, H., Rangachari, D., VanderLaan, P., Costa, D.> ;JTO Clinical and Research Reports. 2024 Jan 1
• Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
  Xiuning Le, Eric Nadler, Daniel B Costa, John Victor Heymach> ;Targeted Oncology. 2024 Jan 1
• Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
  Xiuning Le, Eric Nadler, Daniel B Costa, John Victor Heymach> ;Targeted Oncology. 2023 Nov 1
• 1 citations
  EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.
  Xiuning Le, Eric Nadler, Daniel B Costa, John Victor Heymach> ;Targeted Oncology. 2023 Nov 1
• 5 citations
  exon 20 insertion mutations andmutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.
  Daniel Sentana-Lledo, Emmeline Academia, Hollis Viray, Deepa Rangachari, Susumu S Kobayashi, Paul A VanderLaan, Daniel B Costa> ;Translational Lung Cancer Research. 2023 Jul 31
• 1 citations
  EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeuti...
  William Shaffer, Daniel Sentana-Lledo, Shriram Sundararaman, Meghan D Lee, Deepa Rangachari, Paul A VanderLaan, Susumu S Kobayashi, Daniel B Costa, Kobayashi, I.> ;Lung Cancer. 2023 Jul 1
• 3 citations
  Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer.
  Daniel Sentana-Lledo, Hollis Viray, Andrew J Piper-Vallillo, Page Widick, Deepa Rangachari, Jennifer L Wilson, Sidharta P Gangadharan, Joseph A Aronovitz, Stuart M Ber...> ;Lung Cancer. 2022 Oct 1
• 7 citations
  EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion ...
  Ikei S Kobayashi, Hollis Viray, Deepa Rangachari, Susumu S Kobayashi, Daniel B Costa> ;Cells. 2021 Dec 17
• 7 citations
  Stereotactic Ablative Radiotherapy for High-Risk Prostate Cancer-a Prospective Multi-level MRI-based Dose Escalation Trial.
  Raquibul Hannan, Samer Salamekh, Neil Desai, Aurelie Garant, Michael R. Folkert, Daniel N. Costa, Samantha Mannala, Chul Ahn, Osama Mohamad, Aaron Laine, Dong W. Natha...> ;International Journal of Radiation Oncology, Biology, Physics. 2021 Nov 10
• 3 citations
  PI-RADS and Likert scales for structured reporting in multiparametric MR imaging of the prostate.
  Shivang Desai, Daniel N. Costa> ;The British Journal of Radiology. 2021 Sep 29
• 118 citations
  Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
  Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazh...> ;Cancer Discovery. 2021 Jul 1
• 12 citations
  Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer
  Kartik Sehgal, Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri, Danielle C. McDonald, Cynthia R. Cherry, Meghan Shea, Mark S. Hub...> ;Clinical Lung Cancer. 2021 May 1
• 13 citations
  Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
  Kartik Sehgal, Deepa Rangachari, Paul A. VanderLaan, Susumu Kobayashi, Daniel B. Costa> ;The Oncologist. 2021 Apr 1
• Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations.
  Andrew J. Piper-Vallillo, Susumu Kobayashi, Daniel B. Costa> ;JTO Clinical and Research Reports. 2021 Mar 1
• 20 citations
  Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations.
  Pedro E.N.S. Vasconcelos, Ikei S. Kobayashi, Susumu Kobayashi, Daniel B. Costa> ;JTO Clinical and Research Reports. 2021 Mar 1
• 12 citations
  The Rapidly Evolving Landscape of Biomarker Testing in Non-Small Cell Lung Cancer
  Paul A. VanderLaan, Deepa Rangachari, Daniel B. Costa> ;Cancer Cytopathology. 2021 Mar 1
• 5 citations
  Time to SARS-CoV-2 clearance among patients with cancer and COVID-19.
  Wenxin Xu, Andrew J. Piper-Vallillo, Poorva Bindal, Jonathan W. Wischhusen, Jaymin M. Patel, Daniel B. Costa, Mary Linton B. Peters> ;Cancer Medicine. 2021 Feb 9
• 62 citations
  Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
  Kartik Sehgal, Ritu R. Gill, Page Widick, Poorva Bindal, Danielle C. McDonald, Meghan Shea, Deepa Rangachari, Daniel B. Costa> ;JAMA Network Open. 2021 Feb 1
• 4 citations
  Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer.
  Joel W. Neal, Daniel B. Costa, Alona Muzikansky, Joseph B. Shrager, Michael Lanuti, James Huang, Kavitha J Ramachandran, Deepa Rangachari, Mark S. Huberman, Zofia Piot...> ;JCO Precision Oncology. 2021 Feb 1
• 28 citations
  PI-RADS Version 2.1: A Critical Review, From the AJR Special Series on Radiology Reporting and Data Systems.
  Andrei S. Purysko, Ronaldo Hueb Baroni, Francesco Giganti, Daniel B. Costa, Raphaële Renard-Penna, Chan Kyo Kim, Steven S. Raman> ;AJR. American Journal of Roentgenology. 2021 Jan 1
• 13 citations
  Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC.
  Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, Kartik Sehgal, Adam Miller, Kenneth L. Kehl, Deepti Venkatraman, Jacob Sands, Giuseppe Lamberti, Gonzalo Recondo,...> ;JTO Clinical and Research Reports. 2020 Nov 1
• In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer
  Poorva Bindal, Page Widick, Daniel B. Costa, Deepa Rangachari> ;Translational Cancer Research. 2020 Oct 3
• 5 citations
  Time to SARS-CoV-2 Clearance Among Patients with Cancer and COVID-19.
  Wenxin Xu, Andrew J. Piper-Vallillo, Poorva Bindal, Jonathan W. Wischhusen, Jaymin M. Patel, Daniel B. Costa, Mary Linton B. Peters> ;Medrxiv. 2020 Jul 24
• 13 citations
  Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
  Kartik Sehgal, Daniel B. Costa, Deepa Rangachari> ;Frontiers in Oncology. 2020 Jun 23
• Join now to see all